Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Enzalutamide & Prostate cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Enzalutamide is approved by both the FDA and EMA for prostate cancer, specifically for various forms of castration-resistant prostate cancer (CRPC), including metastatic and nonmetastatic cases (1, 2, 3)

References:

(1) Ning et al. 2015 Oncologist 20(8): 960-6
(2) Pal et al. 2013 Expert Opin Pharmacother 14(5): 679-85
(3) Ramadan et al. 2015 Onco Targets Ther 8: 871-6

see also:
Androgen Receptor (AR) antagonists / Androgen receptor inhibitors / Antiandrogens & Prostate Cancer
[Pros…

References (Sources)

Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis
Roumiguié et al. 2021 Future Oncology 17: 1811–1823
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Sternberg et al. 2020 NEJM 382: 2197-2206
Enzalutamide for patients with metastatic castration-resistant prostate cancer
Ramadan et al. 2015 Onco Targets Ther 8: 871-6
Review
Enzalutamide for the treatment of prostate cancer
Pal et al. 2013 Expert Opin Pharmacother 14(5): 679-85
Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
Hilal et al. 2020 JAMA Intern. Med. 180: 1108
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Antonarakis et al. 2023 J Clin Oncol 41: 3839-3850
U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Ning et al. 2015 Oncologist 20(8): 960-6

AI Chat

7/1/2026

Chat with our artificial intelligence: